Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Botanix Pharmaceuticals Limited ( (AU:BOT) ) is now available.
Botanix Pharmaceuticals announced that its sublicensee, Dongwha Pharm. Co., Ltd., has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. This approval marks a significant step in Botanix’s expansion into Asian markets, following the successful launch of ECCLOCK in Japan by Kaken Pharmaceutical Co. Ltd. Dongwha plans to commercialize ECCLOCK in South Korea by the first quarter of 2026, enhancing its product portfolio. Although Botanix will receive a portion of the royalties from sales in South Korea, the company does not expect this revenue to be material. However, the agreement provides Botanix with opportunities for ongoing growth through potential sublicensing and commercialization outside of Asian territories.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, US, known for its innovative solutions in clinical dermatology. The company has received FDA approval for its lead product Sofdra, which is the first and only new chemical entity approved for treating primary axillary hyperhidrosis, a condition with limited treatment options.
Average Trading Volume: 14,972,251
Technical Sentiment Signal: Sell
Current Market Cap: A$274.6M
See more insights into BOT stock on TipRanks’ Stock Analysis page.